anti-CD3 x anti-CD123 bispecific antibody

An anti-CD3 x anti-CD123 bispecific antibody is a type of bispecific monoclonal antibody designed to engage both T cells and leukemic cells. It simultaneously binds to the CD3 receptor on T cells and the CD123 (interleukin-3 receptor alpha) antigen, which is highly expressed on acute myeloid leukemia (AML) blasts and leukemic stem cells (LSCs). By bringing these two cell types into close proximity, the bispecific antibody triggers T-cell activation and redirects T-cell-mediated cytotoxicity to selectively destroy CD123-expressing leukemic cells. Several candidates of this class, such as mipletamig (APVO436) and flotetuzumab, have been investigated in clinical trials for the treatment of hematological malignancies, particularly relapsed or refractory acute myeloid leukemia (AML) and myelodysplastic syndromes (MDS).

Other names

CD123 x CD3 bispecific antibodyCD-123 x CD3 bispecific antibodyCD 123 x CD3 bispecific antibodyCD123 x CD3 bispecific monoclonal antibodyCD-123 x CD3 bispecific monoclonal antibodyCD 123 x CD3 bispecific monoclonal antibodyCD123BiCD-123BiCD 123BiCD3 x CD123 bispecific antibodyCD-3 x CD123 bispecific antibodyCD 3 x CD123 bispecific antibodyCD3 x CD123 bispecific monoclonal antibodyCD-3 x CD123 bispecific monoclonal antibodyCD 3 x CD123 bispecific monoclonal antibodyanti-CD123 x anti-CD3 bispecific antibodyanti-CD-123 x anti-CD3 bispecific antibodyanti-CD 123 x anti-CD3 bispecific antibodyanti-CD123 x anti-CD3 bispecific monoclonal antibodyanti-CD-123 x anti-CD3 bispecific monoclonal antibodyanti-CD 123 x anti-CD3 bispecific monoclonal antibodyanti-CD3 x anti-CD123 bispecific monoclonal antibodyanti-CD-3 x anti-CD123 bispecific monoclonal antibodyanti-CD 3 x anti-CD123 bispecific monoclonal antibody